To access this element change to forms mode OFF
Grant Award View - GA29845
Tailored priming of pancreatic cancer progression and metastatic...
GA ID:
GA29845
Agency:
National Health and Medical Research Council (NHMRC)
Approval Date:
25-Oct-2018
Publish Date:
21-Dec-2018
Category:
Medical Research
Grant Term:
1-Jan-2019 to 31-Dec-2022
Value (AUD):
$892,362.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
NHMRC 17/18 1.1 Health and Medical Research
Grant Program:
Project
Grant Activity:
Tailored priming of pancreatic cancer progression and metastatic targeting using KD025, a phase II (ROCK2) inhibitor: fine-tuning treatment via single cell intravital imaging
Purpose:
Inefficient drug response in solid tumour tissue is commonly a limiting factor in the clinical effectiveness of cancer therapies. Using cutting-edge imaging technology and 3D models that mimic the disease, we have mapped areas of poor drug response within distinct regions of tumours. Here, we pinpoint and specifically target key factors limiting efficient drug targeting in order to improve the encouraging anti-cancer profile of the new drug combination Gemcitabine/Abraxane in pancreatic cancer.
GO ID:
GO Title:
NHMRC Project Grant Scheme
Internal Reference ID:
GNT1160022
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
Garvan Institute of Medical Research
Recipient ABN:
62 330 391 937
Grant Recipient Location
Suburb:
Darlinghurst
Town/City:
Darlinghurst
Postcode:
2010
State/Territory:
NSW
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
NSW, Overseas
Postcode:
Multiple
Country:
AUSTRALIA, UNITED KINGDOM, UNITED STATES